These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32583337)

  • 1. Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.
    Finlay AK; Morse E; Stimmel M; Taylor E; Timko C; Harris AHS; Smelson D; Yu M; Blue-Howells J; Binswanger IA
    J Gen Intern Med; 2020 Sep; 35(9):2529-2536. PubMed ID: 32583337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
    Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
    Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
    [No Abstract]   [Full Text] [Related]  

  • 3. Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study.
    Morse E; Binswanger IA; Taylor E; Gray C; Stimmel M; Timko C; Harris AHS; Smelson D; Finlay AK
    J Subst Abuse Treat; 2021 Oct; 129():108353. PubMed ID: 34080564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System.
    Grella CE; Ostile E; Scott CK; Dennis M; Carnavale J
    Int J Drug Policy; 2020 Jul; 81():102768. PubMed ID: 32446130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
    Finlay AK; Harris AH; Rosenthal J; Blue-Howells J; Clark S; McGuire J; Timko C; Frayne SM; Smelson D; Oliva E; Binswanger I
    Drug Alcohol Depend; 2016 Mar; 160():222-6. PubMed ID: 26832998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians.
    Booty MD; Harp K; Batty E; Knudsen HK; Staton M; Oser CB
    J Subst Use Addict Treat; 2023 Jun; 149():209051. PubMed ID: 37084815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities in Access to Medications for Opioid Use Disorder in the Veterans Health Administration.
    Finlay AK; Harris AHS; Timko C; Yu M; Smelson D; Stimmel M; Binswanger IA
    J Addict Med; 2021 Apr; 15(2):143-149. PubMed ID: 32826617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration.
    Taylor E; Timko C; Harris AHS; Yu M; Finlay AK
    Addict Sci Clin Pract; 2019 Jan; 14(1):1. PubMed ID: 30602392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention.
    Gustavson AM; Kenny ME; Wisdom JP; Salameh HA; Ackland PE; Gordon AJ; Hagedorn HJ
    Addict Sci Clin Pract; 2021 Aug; 16(1):51. PubMed ID: 34362445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy- and parenting-related barriers to receiving medication for opioid use disorder: A multi-paneled qualitative study of women in treatment, women who terminated treatment, and the professionals who serve them.
    Apsley HB; Brant K; Brothers S; Harrison E; Skogseth E; Schwartz RP; Jones AA
    Womens Health (Lond); 2024; 20():17455057231224181. PubMed ID: 38362719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Project ECHO to promote evidence based care for justice involved adults with opioid use disorder.
    Adams ZW; Agley J; Pederson CA; Bell LA; Aalsma MC; Jackson T; Grant MT; Ott CA; Hulvershorn LA
    Subst Abus; 2022; 43(1):336-343. PubMed ID: 34283701
    [No Abstract]   [Full Text] [Related]  

  • 12. Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia.
    Staton M; Pike E; Tillson M; Lofwall MR
    J Community Psychol; 2024 Nov; 52(8):997-1014. PubMed ID: 36930568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracking the randomized rollout of a Veterans Affairs opioid risk management tool: A multi-method implementation evaluation using the Consolidated Framework for Implementation Research (CFIR).
    McCarthy SA; Chinman M; Rogal SS; Klima G; Hausmann LRM; Mor MK; Shah M; Hale JA; Zhang H; Gordon AJ; Gellad WF
    Implement Res Pract; 2022; 3():26334895221114665. PubMed ID: 37091078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: Application of the consolidated framework for implementation research in a cross-system initiative.
    Hanna J; Kubiak S; Pasman E; Gaba A; Andre M; Smelson D; Pinals DA
    J Subst Abuse Treat; 2020 Jan; 108():104-114. PubMed ID: 31285078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health, Polysubstance Use, and Criminal Justice Involvement Among Adults With Varying Levels of Opioid Use.
    Winkelman TNA; Chang VW; Binswanger IA
    JAMA Netw Open; 2018 Jul; 1(3):e180558. PubMed ID: 30646016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid Agonist Treatment Recipients within Criminal Justice-Involved Populations.
    Guastaferro WP; Koetzle D; Lutgen-Nieves L; Teasdale B
    Subst Use Misuse; 2022; 57(5):698-707. PubMed ID: 35172673
    [No Abstract]   [Full Text] [Related]  

  • 17. The influence of familial networks and stigma on prison-based medication initiation for individuals with opioid use disorder: Clinicians' perceptions.
    Rockett ML; Knudsen HK; Oser CB
    J Subst Use Addict Treat; 2024 Jul; 162():209353. PubMed ID: 38521351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative.
    Krawczyk N; Bandara S; Merritt S; Shah H; Duncan A; McEntee B; Schiff M; Ahmad NJ; Whaley S; Latimore A; Saloner B
    Addict Sci Clin Pract; 2022 Jun; 17(1):30. PubMed ID: 35655293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative attitudes about medications for opioid use disorder among criminal legal staff.
    Moore KE; Siebert SL; Kromash R; Owens MD; Allen DC
    Drug Alcohol Depend Rep; 2022 Jun; 3():100056. PubMed ID: 36845981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers.
    Pivovarova E; Taxman FS; Boland AK; Smelson DA; Lemon SC; Friedmann PD
    J Subst Use Addict Treat; 2023 Apr; 147():208950. PubMed ID: 36804347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.